Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems
- PMID: 1991683
- DOI: 10.1016/0360-3016(91)90095-l
Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems
Abstract
Cytotoxic drugs were administered either in single or fractionated doses before, during, or after a standard course of 5 daily X ray exposures. SCCVII and RIF-1 tumors were grown from cells implanted in the gastrocnemius muscles of syngeneic C3H/Km mice, and treatments were evaluated by regrowth delay (GD). Non-tumor-bearing mice were irradiated locally to the upper abdomen for analysis of intestinal crypt cell survival, an acute normal tissue effect; other non-tumor-bearing mice were irradiated locally to the thorax for analysis of early (pneumonitis) and late (fibrosis) effects on the lungs, as reflected in changes in breathing rates. In a series of experiments to test the combination of i.p. 5-FU, cis-DDP, and X ray, dose effect factors (DEF's) were compared so that therapeutic gain factors (TGF's) could be calculated from the ratio, DEF (tumor)/DEF (normal tissue). The highest TGF, 6.7 (tumor/duodenum), was obtained for the schedule in which 100 mg/kg 5-FU was given 24 hr before the simultaneous administration of 1.6 mg/kg cis-DDP and X ray for 5 consecutive days. The following summary refers only to tumor growth delay data. In confirmation of previous extensive experiments, the combination of cis-DDP + X ray showed supra-additivity, whether the drug was given in a single dose (abbreviated P) or simultaneously with X ray (abbreviated px), that is, P x x x x x or px px px px px. For CY + X ray, the greatest supra-additivity was obtained for either C x x x x x or x x x x x C. 5-FU alone did not act supra-additively with fractionated irradiation, but the addition of 5-FU to cis-DDP + X ray was supra-additive for certain schedules, maximally for F px px px px px. CY combined to give greater than additivity with either cis-DDP or X ray alone, and the combination of CY + cis-DDP + X ray appeared to be supra-additive for five different schedules, maximally for C x x x x x P. Normal tissue effects are being evaluated for these same schedules so that TGF's might soon be obtained.
Similar articles
-
The effect of treatment in fractionated schedules with the combination of X-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin.Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):111-21. doi: 10.1016/0360-3016(85)90369-4. Int J Radiat Oncol Biol Phys. 1985. PMID: 4038500
-
Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse.Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1523-32. doi: 10.1016/0360-3016(87)90320-8. Int J Radiat Oncol Biol Phys. 1987. PMID: 3624028
-
Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/Km mouse model systems.Cancer Res. 1988 Jun 1;48(11):3158-64. Cancer Res. 1988. PMID: 2966671
-
The importance of schedule and drug dose intensity in combinations of modalities.Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):761-71. doi: 10.1016/0360-3016(94)90205-4. Int J Radiat Oncol Biol Phys. 1994. PMID: 8113123 Review.
-
Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data.Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26. doi: 10.1016/0360-3016(87)90015-0. Int J Radiat Oncol Biol Phys. 1987. PMID: 3549645 Review.
Cited by
-
Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results.Strahlenther Onkol. 1999 Mar;175(3):97-101. doi: 10.1007/BF02742341. Strahlenther Onkol. 1999. PMID: 10093610 Clinical Trial.
-
Chemoradiotherapy: the new standard care for invasive cervical cancer.Drugs. 2000 Dec;60(6):1239-44. doi: 10.2165/00003495-200060060-00001. Drugs. 2000. PMID: 11152009
-
Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.Cancer Chemother Pharmacol. 1993;33(3):203-9. doi: 10.1007/BF00686217. Cancer Chemother Pharmacol. 1993. PMID: 8269601 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous